APEX1 and colonic neoplasm: In 2018, Huajun reported that patients with colon cancer had significantly higher plasma anti-APE1/Ref-1 autoantibody levels (2.68 ± 0.34 ng/mL) compared with the control group (1.83 ± 0.31 ng/mL; p < 0.001) [22].